Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI) -- Ignore unavailable to you. Want to Upgrade?

To: Grant MacMillan who wrote (2153)	11/13/1998 1:51:00 PM
From: greg Benfield	Respond to of 2887

IMO, The omnicath and Omnifilter are the two most important products. The others are not as explosive. Regardless, I think $18MM for the company now would be considered an incredible bargain...but again that is just my opinion. I think the company is worth about $5/share currently with an upside of $7/share.

To: Grant MacMillan who wrote (2153)	11/13/1998 2:22:00 PM
From: Jeffrey L. Henken	Read Replies (1) \| Respond to of 2887

>Jeff, you mention the selling of non-core technologies.< I'm not certain what technologies the company might be referring to when they make these statements but I suspect the most valuable would be the stents. Arterial Vascular Engineering bought World medical earlier this year for their AAA Talent stent system currently under development. They paid $59 million dollars for the company. American BioMed's technology may actually be superior. In my opinion the patent alone on the Y shaped or bifurcated stent should be worth more than US Surgical offered for American BioMed in 1995. >Considering your own earnings projections, do you consider any of their current products on the market as being core, or is the OmniCath & Omnifilter the only products worth focusing on?< I would never sell the Omnifilter. The market for such a product could exceed the numbers being achieved by the current sales of market leader AVEI's stent line. The OmniCath? I would like to see a strategic partner to help complete development and insure sales. I feel the same about the Omnifilter. >Also, the $18MM offer from two years ago (sorry I don't know more about it), do you now consider their not accepting that offer a mistake, or were they after patents which would have left no future for ABMI?< The offer would be woefully inadequate today. I don't know the exact terms that were offered or exactly what fell apart and when but I do know that $18 million for this company today would be consider an absolute joke by the majority of it's shareholders. American BioMed needs to announce funding, get cooking on R&D and find those strategic partners. I personally am no longer interested in a buyout. I want to see American BioMed find a way to see it's own chance at real success. I have said this before and I'll say it again: The settlement of the Dr Summers suit makes everything possible for American BioMed. These 27 patents are worth an enormous amount of money as long as American BioMed has the money to continue R&D. Why has American BioMed not been purchased to date? Two reasons: First Dr Summers might actually have won that lawsuit. He could own those patents. Second the company has consistently been scraping by to date and anyone interested in buying ABMI might have been waiting for the going out of business sale. I realize this is only speculation but it could still be true today. An announcement on funding is absolutely crucial. We need LaSalle or someone else to come through for American BioMed with funding and do it in a non dilutional fashion. I think they will because the return on investment for a company that could sell enough Omnifilters to make the kind of money AVEI is making could be enormous. Regards, Jeff